
    
      This compassionate use program will consist of a Pretreatment Phase and a Treatment Phase.
      Patients with locally advanced or metastatic breast cancer who fulfill the eligibility
      criteria may be treated. Safety data will be collected, but a minimal amount of other data
      will also be collected.
    
  